CytomX Therapeutics (CTMX) Misses Q3 EPS by 4c

CytomX Therapeutics (NASDAQ: CTMX) reported Q3 EPS of ($0.09), $0.04 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $11.84 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.

You May Also Be Interested In

• Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
• Traws Pharma (TRAW) Tops Q2 EPS by 27c
• Laser Photonics Corporation (LASE) Reports Q2 Loss of $0.08